Ignite Creation Date:
2024-05-05 @ 5:13 PM
Last Modification Date:
2024-10-26 @ 9:29 AM
Study NCT ID:
NCT00417677
Status:
TERMINATED
Last Update Posted:
2007-12-28
First Post:
2007-01-02
Brief Title:
A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced Renal Cell Carcinoma
Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Organization:
Wyeth is now a wholly owned subsidiary of Pfizer
Study Overview
Official Title:
A Phase III Study of Temsirolimus and Sunitinib in Subjects With Advanced Renal Cell Carcinoma
Status:
TERMINATED
Status Verified Date:
2007-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Decision was made not to attempt a lower dose
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is being conducted to determine the Maximum Tolerated Dose MTD and efficacy of the combined treatment of Temsirolimus and Sunitinib for the treatment of Advanced Kidney Cancer
Detailed Description:
A study to determine the safety tolerability and maximum tolerated dose MTD of the combination of temsirolimus and sunitinib in subjects with advanced Renal Cell Carcinoma RCC dose escalation phase Once the MTD is determined this study will also evaluate the efficacy of this combination by determining progression free survivial PFS at 12 months in subjects with advanced RCC expanded cohort phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None